



*tpw*

PATENT  
ATTORNEY DOCKET NO. 50304/054001

Certificate of Mailing: Date of Deposit: March 20, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Juliann Raymond

Printed name of person mailing correspondence

*Juliann Raymond*

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Neyts et al.	Confirmation No.:	5115
Serial No.:	10/519,756	Art Unit:	1617
Filed:	December 30, 2004	Examiner:	Shengjun Wang
Customer No.:	21559		
Title:	VIRAL INHIBITORS		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Date:

March 29, 2007

Respectfully submitted,



James D. DeCamp, Ph.D.  
Reg. No. 43,580

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

J. Cooper McDonald, Ph.D.  
Reg. No. 52,011



SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50304/054001 Serial No. 10/519,756 Applicant Neyts et al. Filing Date December 30, 2004 Group 1617 IDS Filed March 20, 2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		
(37 C.F.R. § 1.98(b))		

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	3,985,891	10/12/76	Kutter et al.			
	4,565,816	01/21/86	Neumann			
	4,692,443	09/08/87	Katner			
	4,804,658	02/14/89	Manley et al.			
	4,914,108	04/03/90	Khanna et al.			
	4,988,707	01/29/91	Stealey et al.			
	4,990,518	02/05/91	Khanna et al.			
	5,019,581	05/28/91	Khanna et al.			
	5,057,517	10/15/91	Johnston et al.			
	5,137,896	08/11/92	Van Daele			
	5,208,242	05/04/93	Khanna et al.			
	5,227,384	07/13/93	Khanna et al.			
	5,302,601	04/12/94	Khannal et al.			
	5,332,744	07/26/94	Chakravarty et al.			
	5,374,638	12/20/94	Dhanoa et al.			
	5,405,964	04/11/95	Mederski et al.			
	5,438,063	08/01/95	Osswald et al.			
	5,486,525	01/23/96	Summers, Jr. et al.			
	5,587,372	12/24/96	Aszodi et al.			
	5,607,944	03/04/97	Linz et al.			
	6,329,381 B1	12/11/01	Kurimoto et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50304/054001 10/519,756 Neyts et al. December 30, 2004 1617 March 20, 2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					
(37 C.F.R. § 1.98(b))					

	6,479,508 B1	11/12/02	Beaulieu et al.			
	6,492,384 B1	12/10/02	Mederski et al.			
	6,770,666 B2	08/03/04	Hashimoto et al.			
	7,112,600 B1	09/26/06	Hashimoto et al.			
	2004/0082635 A1	04/29/04	Hashimoto et al.			
	2003/0108862 A1	06/12/03	Kukolj et al.			
	2004/0097438 A1	05/20/04	Hashimoto et al.			
	2004/0097574 A1	05/20/04	Marshall			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	CA 2 357 771	07/13/00	Canada			
	DE 42 11 474 A1	10/07/93	Germany			No
	DE 42 30 464 A1	03/17/94	Germany			No
	DE 42 36 026 A1	04/28/94	Germany			No
	DE 43 09 969 A1	09/29/94	Germany			No
	DE 43 18 813 A1	12/08/94	Germany			No
	EP 0 076 530 B1	04/13/83	EPO			
	EP 0 138 552 A2	04/24/85	EPO			
	EP 0 232 937 A2	08/19/87	EPO			
	EP 0 300 726 A1	01/25/89	EPO			
	EP 0 300 726 B1	01/25/89	EPO			
	EP 0 344 414 A1	12/06/89	EPO			
	EP 0 344 414 B1	12/06/89	EPO			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/054001
	Serial No.	10/519,756
	Applicant	Neyts et al.
	Filing Date	December 30, 2004
	Group	1617
	IDS Filed	March 20, 2007

	EP 0 462 009 B1	12/18/91	EPO			Abstract Only
	EP 0 510 260 A2	10/28/92	EPO			
	EP 0 605 836 A1	07/13/94	EPO			
	EP 0 706 795 A2	04/17/96	EPO			
	EP 1 132 381 A1	09/12/01	EPO			
	EP 1 162 196 A1	12/12/01	EPO			
	EP 1 400 241 A1	03/24/04	EPO			
	GB 2 158 440 A	11/13/85	Great Britain			
	GB 2 264 115 A	08/18/93	Great Britain			
	HU 78019	05/28/95	Hungary			
	SU 813921 A	12/23/86	Soviet Union			No
	SU 851940 A	04/30/88	Soviet Union			No
	SU 860463 A1	05/27/98	Soviet Union			Yes - Abstract
	SU 1048742 A	12/23/86	Soviet Union			No
	WO 92/22556 A1	12/23/92	WIPO			
	WO 93/02080 A1	02/04/93	WIPO			
	WO 93/14072 A1	07/22/93	WIPO			
	WO 93/16075 A1	08/19/93	WIPO			
	WO 94/12461 A1	06/09/94	WIPO			
	WO 94/29321 A1	12/22/94	WIPO			
	WO 95/02597 A1	01/26/95	WIPO			
	WO 95/16687 A1	06/22/95	WIPO			
	WO 96/11192 A1	04/18/96	WIPO			
	WO 96/12703 A1	05/02/96	WIPO			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/054001
	Serial No.	10/519,756
	Applicant	Neyts et al.
	Filing Date	December 30, 2004
	Group	1617
	IDS Filed	March 20, 2007

	WO 99/27929 A1	06/10/99	WIPO			
	WO 00/20416 A1	04/13/00	WIPO			Abstract Only
	WO 00/39127 A1	07/06/00	WIPO			
	WO 00/40583 A2	07/13/00	WIPO			Abstract Only
	WO 00/40586 A1	07/13/00	WIPO			Abstract Only
	WO 01/60315 A2	08/23/01	WIPO			
	WO 01/85172 A1	11/15/01	WIPO			
	WO 02/04425 A2	01/17/02	WIPO			
	WO 02/057425 A2	07/25/02	WIPO			
	WO 03/007945 A1	01/30/03	WIPO			
	WO 03/010140 A2	02/06/03	WIPO			
	WO 03/010141 A2	02/06/03	WIPO			
	WO 03/026587 A2	04/03/03	WIPO			
	WO 04/005286 A2	01/15/04	WIPO			
	WO 04/005286 A3	01/15/04	WIPO			
	WO 04/019935 A1	03/11/04	WIPO			

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Akamatsu et al., "New Efficient Route for Solid-Phase Synthesis of Benzimidazole Derivatives," <i>J. Comb. Chem.</i> 4:475-483 (2002).
	Baginski et al., "Mechanism of Action of a Pestivirus Antiviral Compound," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 97:7981-7986 (2000).
	Barlin, "Ionisation Constants of Heterocyclic Substances. Part VIII. 1,3,5-Triazaindenes," <i>J. Chem. Soc. B: Phys. Org.</i> 4:285-291 (1966).
	Barlin and Fenn, "A Carbon-13 Nuclear Magnetic Resonance Study of Protonation in Imidazo[4,5-c]pyridines," <i>Aust. J. Chem.</i> 34:1341-1344 (1981).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/054001
	Serial No.	10/519,756
	Applicant	Neyts et al.
	Filing Date	December 30, 2004
	Group	1617
	IDS Filed	March 20, 2007

	Barlin and Fenn, "The Preparation and <sup>1</sup> H NMR Spectra of Some N-Methylpurines and Related Compounds," <i>Aust. J. Chem.</i> 36:633-638 (1983).
	Barracough et al., "An Adventitious Synthesis of a 5-Methylimidazo[4,5-c]pyridine Derivative," <i>Tet. Lett.</i> 27:5997-6000 (1986).
	Barracough et al., "Inotropic "A" Ring Substituted Sulmazole and Isomazole Analogues," <i>J. Med. Chem.</i> 33:2231-2239 (1990).
	Brown et al., "Purine Analogues as Amplifiers of Phleomycin. V. Thioethers of Several Heterocyclic Systems with One or Two Rings," <i>Aust. J. Chem.</i> 32:2713-2726 (1979).
	Cleve et al., "Derivate des Imidazo[4,5-b]- und Imidazo[4,5-c]pyridins," <i>Liebigs Ann. Chem.</i> 747:158-171 (1971).
	Curtin et al., "Discovery and Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Antagonists," <i>J. Med. Chem.</i> 41:74-95 (1998).
	Kiyama et al., "Synthesis and Evaluation of Novel Nonpeptide Angiotensin II Receptor Antagonists: Imidazo[4,5-c]pyridine Derivatives with an Aromatic Substituent," <i>Chem. Pharm. Bull.</i> 43:450-460 (1995).
	Mederski and Pachler, "Synthesis and Structural Assignment of Some N-Substituted Imidazopyridine Derivatives," <i>Tetrahedron</i> 48:10549-10558 (1992).
	Robertson et al., "Structure-Activity Relationships of Arylimidazopyridine Cardiotonics: Discovery and Inotropic Activity of 2-[2-Methoxy-4-(methylsulfinyl)phenyl]-1 <i>H</i> -imidazo[4,5-c]pyridine," <i>J. Med. Chem.</i> 28:717-727 (1985).
	Savarino et al., "Spectral Behaviour of Linked Heterocyclic Systems and Related Dyes," <i>Spectrochim. Acta A: Mol. Biomol. Spectrosc.</i> 49A:1379-1393 (1993).
	Stanovnik et al., "Methylation of Heterocyclic Compounds Containing NH, SH, and/or OH Groups by Means of N,N-Dimethylformamide Dimethyl Acetal," <i>Aust. J. Chem.</i> 34:1729-1738 (1981).
	Vassilev et al., "Authentic and Chimeric Full-Length Genomic cDNA Clones of Bovine Viral Diarrhea Virus That Yield Infectious Transcripts," <i>J. Virol.</i> 71:471-478 (1997).
	Wang et al., "Non-Nucleoside Analogue Inhibitors Bind to an Allosteric Site on HCV NS5B Polymerase. Crystal Structures and Mechanism of Inhibition," <i>J. Biol. Chem.</i> 278:9489-9495 (2003).
	Yutilov et al., "Synthesis and Antiviral Activity of Spinaceamine," <i>Khim. Farm. Zh.</i> 23:56-59 (1989).
	Zhang, "Inhibitors of Hepatitis C -- A Review of the Recent Patent Literature," <i>IDrugs</i> 5:154-158 (2002).
	International Preliminary Examination Report (PCT/BE03/00117) (mailed 3 September, 2004).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	